Basic science insights along with the assessment of risk factors so clearly documented by the Canadian and Hopkins cohorts in earlier papers of this special issue have clearly led to a change in the way rheumatologists manage SLE. This review will highlight specific ways it should alter our day to day treatment of lupus patients.
Ward MM , Pyun E , Studenski S . Causes of death in systemic lupus erythematosus. Long-term follow-up of an inception cohort . Arthritis Rheum1995; 38 (10): 1492–1499 .
2.
Jacobsen S , Petersen J , Ullman S et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factos of prognostic value . Clin Rheumatol1998; 17 (6): 478–484 .
3.
Koh ET , Seow A , Leong KH , Chng HH . SLE mortality in an oriental population . Lupus1997; 6 (1): 27–31 .
4.
Petri M , Perez-Gutthann S , Spence D , Hochberg MC . Risk factors for coronary artery disease in patients with systemic lupus erythematosus . Am J Med1992; 93 (5): 513–519 .
5.
Kannel WB , Castelle WP , Gordon T , McNamara PM . Serum lipoproteins and the risk of coronary artery disease . Ann Intern Med1971; 74: 1–12 .
6.
Roussouw JE . The effects of lowering serum cholesterol on coronary heart disease risk . Med Clin North Am1994; 78: 181–195 .
7.
MacGregor AJ , Dhillon VB , Binder A et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus . Ann Rheum Dis1992; 51 (2): 152–155 .
8.
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . The Expert Panel. 1988; 148 (1): 36–69 .
9.
Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) . Lancet1994; 344: 1383–1389 .
10.
Manninen V , Elo MO , Frick KH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study . JAMA1988; 260: 641–651 .
11.
Lipid Research Clinics Program . The Lipid Research Clinics Coronary Primary Prevention trials. 1. Reduction in incidence of coronary artery disease . JAMA1984; 251: 351–364 .
12.
Coronary Drug Project Research Group . Clofibrate and Niacin in coronary artery disease . JAMA1975; 231: 360–381 .
13.
Wallace DJ , Podell T , Weiner J et al. Lupus nephritis: experience with 230 patients in a private practice from 1950-1980 . Am J Med1982; 72: 209–220 .
14.
Wallace DJ , Metzger AL , Stecher VJ et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids . Am J Med1990; 89 (3): 322–326 .
15.
Rahman P , Gladman DD , Urowitz MB et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs . J Rheumatol1999; 26 (2): 325–330 .
16.
Tsakonas E , Joseph L , Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group . Lupus1998; 7 (2): 80–85 .
17.
van Vollenhoven RF , Engleman EG , McGuire JL . Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial . Arthritis Rheum1995; 38: 1826–1831 .
18.
Tam LS , Li EK , Leung CB et al. Long-term treatement of lupus nephritis with cyclosporin A . QJM1998; 91 (8): 573–580 .
19.
Dooley MA , Cosio FG , Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations . J Am Soc Nephrol1999; 10 (4): 833–839 .
20.
Rahman P , Humphrey-Murto S , Gladman DD , Urowitz MB . Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis . J Rheumatol1998; 25 (2): 243–246 .
21.
Boumpas DT , Austin HA III , Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet1992; 340 (8822): 741–745 .
22.
Petri M , Roubenoff R , Dallal GE et al. Plama homocysteine as a risk facto for atherothrombotic events in systemic lupus erythematosus . Lancet1996; 348 (9035): 1120–1124 .
23.
Fijnheer R , Roest M , Haas FJ et al. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study . J Rheumatol1998; 25 (9): 1737–1742 .
24.
Lahita RG , Rivkin E , Cavanagh I , Romano P . Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus . Arthritis Rheum1993; 36 (11): 1566–1574 .
25.
Greisman SG , Thayaparan RS , Godwin TA , Lockshin MD . Occlusive vasculopathy in systemic lupus erythematosus. Association with anticardioilipin antibody . Arch Intern Med1991; 151: 389–392 .
26.
Cowchock SG , Reece EA , Balaban D et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low dose heparin treatment . Am J Obstet Gynecol1992; 166: 1318–1323 .
27.
Vaarala O , Puurunen M , Likka M et al. Affinity purified cardiolipin binding antibodies show heterogeneity in their binding to oxidized low density lipoprotein . Clin Exp Immunol1996; 104: 269–274 .
28.
Horkko S , Miller E , Dudi E et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids . J Clin Invest1996; 98: 815–825 .
29.
Hasunma Y , Matsuura E , Makita Z et al. Involvement of beta-2 glycoprotein 1 and anticardiolipin antibodies in oxidatively modified low density lipoprotein uptake by macrophages . Clin Exp Immunol1997; 107: 569–573 .
30.
George J , Afek A , Gilburd B et al. Atherosclerosis in LDL receptor knockout mice is accelerated by immunization with anticardiolipin antibodies . Lupus1997; 6: 723–729 .
31.
Bruce IN , Gladman DD , Urowitz MB . Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study . Clin Exp Rheumatol1998; 16 (4): 435–440 .
32.
Meacham LR , Abdul-Latif H , Sullivan K , Culler FL . Predictors of change in insulin sensitivity during glucocorticoid treatment . Horm Metab Res1997; 29 (4): 172–175 .
33.
Ginzler EM , Felson DT , Anthony JM , Anderson JJ . Hypertension increases the risk of renal deterioration in systemic lupus erythematosus . J Rheumatol1993; 20 (10): 1694–1700 .
34.
Naiker IP , Chrystal V , Randeree IGH , Seedat YK . The significance of arterial hypertension at the onset of clinical lupus nephritis . Postgrad Med J1997; 73: 230–233 .
35.
Petri M . Smoking is a risk factor for musculoskeletal, pulmonary and cardiac disease in systemic lupus erythematosus . Lupus1998; 7: (S1) 61-61 .
36.
Brown K , Petri M , Goldman D . Cutaneous manifestations of SLE: Associations with other manifestations of SLE and with smoking . Arthritis Rheum1996; 39: S291-S291 .
37.
Rahman P , Goldman DD , Urowitz MB . Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus . J Rheumatol1998; 25: 1716–1719 .
38.
Ramsey-Goldman R , Chang RW , Dunlop D et al. Exercise in patients with systemic lupus erythematosus (SLE): Pilot study . Arthritis Rheum1995; 38: S242-S242 .
39.
Sturfelt G , Eskilsson J , Nived O et al. Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population . Medicine (Baltimore)1992; 71 (4): 216–223 .
